Compare Amphastar Pharmaceuticals Inc (AMPH) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Barrick Gold Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Barrick Gold Corp trades at $36.21 (market cap $61.25B). The key difference: Barrick Gold Corp is far larger — about 74.1× Amphastar Pharmaceuticals Inc's market cap, and Barrick Gold Corp pays a 1.91% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | B | |
|---|---|---|
Market Cap | $826.08M | $61.25B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $52.97 |
52-Week Low | $16.87 | $20.73 |
Enterprise Value | $1.22B | $58.85B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Barrick Mining (B) trades at $36.68, down 0.41% on the day, with a bearish technical signal but strong fundamentals. The company reported robust 2025 results with revenue of $16.96B and net income of $4.99B, beating earnings estimates in recent quarters. Analyst consensus is strongly bullish with a $51.80 price target, though technical indicators show near-term weakness with support at $36.
The stock presents a value opportunity with a low P/E of 10.07 and strong cash flow growth, but faces headwinds from gold price volatility and bearish momentum. Upside potential exists if Q2 2026 earnings meet or exceed expectations, while risks include commodity price swings and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
